Pfizer Canada Inc. v. Amgen Inc., 2019 FCA 249
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Court of Appeal (Canada) |
| Date | 04 October 2019 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
8 practice notes
-
Table of Cases
...35, 36, 39, 53 O’Hara Manufacturing Ltd v Eli Lilly & Co (1989), 26 CPR (3d) 1 (FCA)...... 180 Pizer Canada Inc v Amgen Inc, 2019 FCA 249 .......................................230, 236 Pizer Canada Inc v Apotex Inc, 2001 CanLII 22156 ........................................224 Pizer Canada......
-
The Patented Medicines (Notice of Compliance) Regulations
...decision on infringement and validity, with an efective right of appeal: Amgen Inc . v. Pfzer Canada Inc ., 2018 FC 1078 at para 27, af’d 2019 FCA 249 at paras 8, 65; Janssen Inc . v. Teva 115 PM(NOC) Regulations, above note 2, s 6(1). See ViiV Healthcare Company, Shionogi & Co Ltd and ViiV......
-
Amgen Inc. v. Pfizer Canada ULC, 2020 FC 522
...and the Federal Court of Appeal upheld her decision (see Amgen Inc v Pfizer Canada Inc, 2018 FC 1078; Pfizer Canada Inc v Amgen Inc, 2019 FCA 249 [Pfizer Canada]). However, relying significantly on its decision in Apotex Inc v Pfizer Ireland Pharmaceuticals, 2011 FCA 77 [Pfizer Ireland], th......
-
Gemak Trust v. Jempak Corporation, 2022 FCA 141
...was one of the inadequacies in the old regime that led to the 2017 changes to the Regulations: Amgen Inc. v. Pfizer Canada Inc., 2019 FCA 249 at para. 23; Regulatory Impact Analysis Statement, Canada Gazette, Part I, Vol. 151, No. 28 on July 15, 2017. The revised NOC Regulations replaced su......
Request a trial to view additional results
4 cases
-
Amgen Inc. v. Pfizer Canada ULC, 2020 FC 522
...and the Federal Court of Appeal upheld her decision (see Amgen Inc v Pfizer Canada Inc, 2018 FC 1078; Pfizer Canada Inc v Amgen Inc, 2019 FCA 249 [Pfizer Canada]). However, relying significantly on its decision in Apotex Inc v Pfizer Ireland Pharmaceuticals, 2011 FCA 77 [Pfizer Ireland], th......
-
Gemak Trust v. Jempak Corporation, 2022 FCA 141
...was one of the inadequacies in the old regime that led to the 2017 changes to the Regulations: Amgen Inc. v. Pfizer Canada Inc., 2019 FCA 249 at para. 23; Regulatory Impact Analysis Statement, Canada Gazette, Part I, Vol. 151, No. 28 on July 15, 2017. The revised NOC Regulations replaced su......
-
Janssen Inc. v. Apotex Inc., 2023 FCA 253
...Inc. v. Novopharm Limited, 2007 FCA 163, 282 D.L.R. (4th) 476 at paras. 26, 35 (Sanofi-Aventis), and Pfizer Canada Inc. v. Amgen Inc., 2019 FCA 249, 311 A.C.W.S. (3d) 823 at para. 57 (Pfizer), this Court has confirmed that the principles enunciated in C.U.P.E. must inform analysis with resp......
-
Sunovion Pharmaceuticals Canada Inc. v. Taro Pharmaceuticals Inc., 2021 FC 37
...decision on infringement and validity, with an effective right of appeal: Amgen Inc. v. Pfizer Canada Inc., 2018 FC 1078 at para 27, aff’d 2019 FCA 249 at paras 8, 65; Janssen Inc. v. Teva Canada Ltd., 2020 FC 593 at para 257; Regulations Amending the Patented Medicines (Notice of Complianc......
2 firm's commentaries
-
Amgen not precluded by invalidity decision under pre-amended PMNOC Regulations from litigating same patent under amended regulations
...would infringe Canadian Patent No. 1,341,537 (537 patent): Pfizer v Amgen, 2019 FCA 249, aff’g 2018 FC 1078 (reported here). Pfizer argued that Amgen’s action ought to be dismissed as an abuse of process on the basis that Amgen had unsuccessfully litigated the same patent under the pre-amen......
-
Federal Court Of Appeal Considers Scope Of Abuse Of Process Under Amended PM(NOC) Regulations
...with an action, including documentary and oral discovery and viva voce evidence presented at a trial. In Pfizer Canada Inc. v. Amgen Inc., 2019 FCA 249, the Federal Court of Appeal (the "Court") considered the differences between actions under section 6 of the Amended Regulations and applic......
2 books & journal articles
-
Table of Cases
...35, 36, 39, 53 O’Hara Manufacturing Ltd v Eli Lilly & Co (1989), 26 CPR (3d) 1 (FCA)...... 180 Pizer Canada Inc v Amgen Inc, 2019 FCA 249 .......................................230, 236 Pizer Canada Inc v Apotex Inc, 2001 CanLII 22156 ........................................224 Pizer Canada......
-
The Patented Medicines (Notice of Compliance) Regulations
...decision on infringement and validity, with an efective right of appeal: Amgen Inc . v. Pfzer Canada Inc ., 2018 FC 1078 at para 27, af’d 2019 FCA 249 at paras 8, 65; Janssen Inc . v. Teva 115 PM(NOC) Regulations, above note 2, s 6(1). See ViiV Healthcare Company, Shionogi & Co Ltd and ViiV......